This study is to evaluate the safety and effectiveness of an injectable slow releasing
preparation of naltrexone to reduce alcohol consumption and risk of relapse in
alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo
injection for a total of three months, with two subsequent followup visits spanning a 6-
- Meets criteria for alcohol dependence.
- Abstinent from alcohol for a period of at least 3 days prior to beginning of study.
- Able to read English and complete study evaluations.
- Females who are postmenopausal, have had surgical sterilization, or use reliable
means of birth control.
- Meets criteria for dependence on a psychoactive substance other than alcohol and
nicotine and/or cannabis.
- Prior history of opioid dependence.
- Regular use of psychoactive drugs including anxiolytics and antidepressants.
- Prior treatment with naltrexone.
- Current use of disulfiram.
- Psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current
- Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid,
or cardiac disease.
- Abstinent longer than 28 days prior to randomization.